None listed
Conditions
Interventions
Drug : - Aripiprazole Monohydrate(Abilify Maintena Inj) : 300mg or 400mg , used an an IM injection into the deep deltoid or gluteus musche, 4Week intervals.
- The switch to aripiprazole long-acting in
Sponsors
Chonnam National University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: ? Diagnosed with schizophrenia utilizing the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) ? Male or female patients who are 19-65 years(inclusive) of age at time of consent ? Patients maintained on current Other dopamine antagonists such as oral or LAI antipsychotics other than Aripiprazole for more than 2 weeks and those should have such as problems efficacy, tolerability, or compliance, per physician judgement or patient's report ? Patients must be fluent in the language of the questionnaires and cooperate in the study ? Patients must be capable of providing signed and dated written informed consent and fully understand the purpose of the study
Exclusion criteria
Exclusion criteria: ? Patients who have current or previous clinically significant findings of physical illness ? Patients with significant suicide risk ? Women who are pregnant, nursing ? Patients with severe drug allergy and severe side effects ? Currently receiving oral aripiprazole monotherapy ? Patients who are participating in drug trials
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Subjective Wellbeing under Neuroleptics-short form | — |
Secondary
| Measure | Time frame |
|---|---|
| Social and Occupational Functioning Scale;Positive and Negative Syndrome Scale | — |
Countries
Korea, Republic of
Contacts
Public ContactAnna Jo
Chonnam National University Hospital
Outcome results
None listed